ANABHealthcare · BiotechnologyThe 8 Wall Street analysts covering AnaptysBio, Inc. hold a median 12-month price target of $80 — +64.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AnaptysBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ANAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +64.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | JP Morgan | Maintains | Overweight | $70 → $60 |
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | $90 → $81 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | $75 → $70 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 24 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 24 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 June 2026 | HC Wainwright & Co. | Assumes | Buy | $95 |
| 13 May 2026 | Barclays | Maintains | Overweight | — |
| 13 May 2026 | UBS | Maintains | Buy | — |
| 4 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 28 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 Apr 2026 | Barclays | Maintains | Overweight | — |
| 21 Apr 2026 | UBS | Maintains | Buy | — |
| 31 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 30 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2026 | UBS | Maintains | Buy | — |
| 12 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 9 Mar 2026 | Truist Securities | Maintains | Hold | — |
| 5 Mar 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ANAB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, AnaptysBio, Inc. returned +98.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 11% of US stocks
Cheaper than 1% of US stocks
Cheaper than 11% of US stocks
Higher than 73% of US stocks
Higher than 28% of US stocks
Higher than 97% of US stocks
Higher than 99% of US stocks
Higher than 26% of US stocks
Higher than 34% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AnaptysBio, Inc. has a market value of $1.5B and an enterprise value of $1.6B.
Revenue in the twelve months to 31 Mar 2026: $232.4M. The latest quarter grew 23.5% year on year.
Net income over the same four quarters: −$26.8M, a −11.5% net margin.
Diluted earnings per share, trailing twelve months: $−1.08.
Free cash flow in the twelve months to 31 Mar 2026: $4.4M, after $69K of capital spending.
AnaptysBio, Inc. spent $64.2M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: −105.0×; forward P/E: 10.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AnaptysBio, Inc. employs 104 people — $2.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AnaptysBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Riverwater Micro Opportunities Strategy reported initiating positions in 908 Devices and Bowhead Specialty Holdings and exiting Coastal Financial in July. The excerpt does not mention AnaptysBio.
Why it matters — The portfolio activity provides no company-specific information about AnaptysBio, so its relevance to ANAB watchers is limited.
The Diamond Hill Small-Mid Cap Fund declined 4.75% in Q3 2026, compared with a 6.37% decline for the Russell 2500 Index. The excerpt names Illumina, Revvity and Waystar as contributors, and Regal Rexnord, Knife River and Red Rock Resorts as detractors.
Why it matters — The excerpt does not mention AnaptysBio, so it provides no company-specific information for ANAB watchers.
Zacks Investment Research says AnaptysBio has two key ingredients associated with a likely earnings beat in its upcoming report, and highlights key expectations.
Why it matters — ANAB watchers may note the article’s positive earnings-beat framing ahead of the company’s upcoming report.
GSK received FDA approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer.
Why it matters — AnaptysBio said it manages the financial collaboration for Jemperli with Tesaro, a GSK company, making the approval relevant to the company’s collaboration activity.
First Tracks Biotherapeutics, an AnaptysBio spinoff, reported “impressive” results for its celiac disease treatment on Monday, and its IPO stock rose by double digits.
Why it matters — The update concerns an AnaptysBio spinoff and its clinical results, making it relevant to ANAB watchers.
The 8 Wall Street analysts covering AnaptysBio, Inc. have a median 12-month price target of $80, with estimates ranging from $60 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering AnaptysBio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AnaptysBio, Inc. 94 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, AnaptysBio, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +64.7% from the last close, and Ticker Nerd's factor model ranks AnaptysBio, Inc. 94 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AnaptysBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $140 over the next 12 months.
AnaptysBio, Inc. returned +98.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases.
The most recent item we track (Seeking Alpha, 30 Oct 2026): "Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity". Riverwater Micro Opportunities Strategy reported initiating positions in 908 Devices and Bowhead Specialty Holdings and exiting Coastal Financial in July. The excerpt does not mention AnaptysBio.
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.
CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.anaptysbio.com
